Latest from Novocure and GT Medical Technologies

Latest from Novocure and GT Medical Technologies

July 22, 2020

Although the official GBM Awareness Day is coming to an end, that doesn’t mean the message and fight behind today is going anywhere. Brains for the Cure, along with so many more in the brain tumor community, will continue to fight each day and provide the latest in brain tumor research and resources.

The standard treatment options for glioblastoma patients has changed very little in the past 30 years. You can read more about the breakdown of a glioblastoma diagnosis in this article from Dr. Simon Khagi. However, two the two companies responsible for creating incredibly innovative devices, Novocure and GT Medical Technologies, continue to move forward and make progress in their research to creating a better quality of life for patients and improving survival rates.

Novocure Announces the First Patient Enrolled in EF-33 Phase 2 Pilot Trial

Novocure, the creator of Optune, announced today that the first patients has been enrolled in its EF-33 Phase 2 Pilot Trial of Tumor Treating Fields in patients with recurrent glioblastoma. According to Novocure, “Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division.”

Learn more about this trial, the Optune Device, and Novocure’s ‘Patient Forward’ approach here.

Upcoming Webinar from GT Medical Technologies

GT Medical Technologies, creator of GammaTile Therapy, announced an upcoming webinar presented by Dr. Clark Chen from the University of Minnesota. GammaTile Therapy is FDA-cleared for newly diagnosed malignant and recurrent brain tumors. Dr. Chen will discuss achieving local tumor control with the use of GammaTile Therapy during the webinar on Monday, July 27th at 7 AM PST. You can register for the webinar here.